|
|
|
|
||||
|
||||
The Globalization of Innovation: Pharmaceuticals: Can India and China Cure the Global Pharmaceutical MarketVivek WadhwaCenter for Entrepreneurship and Research Commercialization, Pratt School of Engineering; Stanford University - Arthur & Toni Rembe Rock Center for Corporate Governance Ben A. RissingMassachusetts Institute of Technology (MIT) - Behavioral Policy Science (BPS) G. GereffiDuke University - Department of Sociology - Director, Center on Globalization, Governance & Competitiveness John TrumpbourHarvard University - Labor and Worklife Program Pete EngardioBusinessWeek Abstract: Multinational pharmaceutical corporations are searching for means to broaden their capacity for drug development while decreasing costs. Pharmaceutical firms in India and China are increasingly forging partnerships with these corporations to gain revenue and to develop their own expertise. These relationships largely appear to be symbiotic. As a result of the movement of research to their countries, Indian and Chinese scientists are rapidly developing the ability to innovate and create their own intellectual property. Several firms in India and China are performing advanced R&D and are moving into the highest-value segments of the pharmaceutical global value chain.
Number of Pages in PDF File: 67 Keywords: pharmaceuticals, innovaiton, R&D, value chain, China, India working papers seriesDate posted: June 11, 2008 ; Last revised: June 13, 2012Suggested CitationContact Information
|
|
||||||||||||||||||||||||
© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.
FAQ
Terms of Use
Privacy Policy
Copyright
This page was processed by apollo7 in 0.485 seconds
